Summary & Overview
HCPCS G9285: Specimen Site Other Than Lung / Not Classified as NSCLC
HCPCS Level II code G9285 denotes cases where the specimen site is not an anatomic location of the lung or the diagnosis is not classified as non–small cell lung cancer. This code applies to pathology and laboratory reporting that clarify specimen origin for oncology diagnostic workflows. Nationally, accurate specimen-site coding supports appropriate clinical classification, billing compliance, and utilization tracking for oncology diagnostics.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for G9285, common payer considerations, and the types of service settings where the code is typically applied. The publication outlines benchmarking topics and policy-relevant points affecting lab and pathology billing practices, including how specimen-site designation influences coding and claim adjudication. It also summarizes typical service lines where G9285 is used and highlights where additional documentation is often required for accurate classification.
This summary is intended for national audiences including coding professionals, billing managers, laboratory directors, and policy analysts seeking a clear description of the code’s clinical meaning, expected service settings, and payer coverage landscape. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code G9285 indicates a specimen site other than anatomic location of lung or is not classified as non small cell lung cancer. The code describes the origin of a specimen used for diagnostic or pathologic classification when the specimen site does not correspond to a lung anatomic location or when the condition is not categorized as non–small cell lung cancer.
Service type: Diagnostic specimen classification and reporting related to oncology/pathology.
Typical site of service: Pathology or laboratory services, including hospital outpatient pathology departments and independent diagnostic laboratories.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with a history of metastatic malignancy undergoes percutaneous biopsy of a pulmonary lesion previously diagnosed as non–small cell lung cancer; however, new tissue is obtained from a metastatic site (for example, a liver or bone lesion) to clarify histology or perform molecular testing because the specimen site is other than the anatomic location of the lung or the tumor is not classified as non–small cell lung cancer. The clinical workflow: the patient is evaluated by medical oncology and interventional radiology or surgical oncology; imaging (CT, ultrasound, or PET) localizes the target lesion; pre-procedure consent and labs are reviewed; image-guided percutaneous core needle or fine-needle aspiration biopsy is performed at the non-pulmonary site; specimens are submitted to pathology for histology, immunohistochemistry, and molecular testing; results guide systemic therapy selection or enrollment in targeted therapy trials. Typical site of service is an outpatient hospital interventional radiology suite, ambulatory surgery center, or inpatient operating room when the patient is admitted. Common clinical indications include characterization of suspected metastatic lesion, change in histologic subtype, or need for repeat tissue for genomic profiling when the lung primary is excluded or tissue is obtained from a non-lung site. Typical patient scenario: symptomatic or asymptomatic metastatic lesion identified on surveillance imaging requiring biopsy for diagnosis, histologic confirmation, or molecular testing where the specimen site is not lung and the lesion may not represent non–small cell lung cancer.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |